107 related articles for article (PubMed ID: 21740817)
1. Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review.
Tang JH; Zhang XL; Zhang ZH; Wang R; Zhang HM; Zhang ZL; Wang JH; Ren WD
Chin Med J (Engl); 2011 May; 124(10):1563-8. PubMed ID: 21740817
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
3. Serum pro-gastrin-releasing peptide in diagnosis of small cell lung cancer: A meta-analysis.
Wang H; Qian J
J Cancer Res Ther; 2016 Dec; 12(Supplement):C260-C263. PubMed ID: 28230031
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis.
Yang HJ; Gu Y; Chen C; Xu C; Bao YX
Clin Chem Lab Med; 2011 Jun; 49(6):1039-46. PubMed ID: 21649553
[TBL] [Abstract][Full Text] [Related]
5. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
6. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications for pro-GRP in small cell lung cancer. A single center experience.
Cavalieri S; Morelli D; Martinetti A; Galli G; Nichetti F; de Braud F; Platania M
Int J Biol Markers; 2018 Jan; 33(1):55-61. PubMed ID: 28967066
[TBL] [Abstract][Full Text] [Related]
8. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of anti-alpha-fodrin antibody testing for Sjögren's syndrome: a meta-analysis].
Huang QS; LE AP; Luo ZQ; Li JM; Wang WQ; Ju BH; Wan LG
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2971-6. PubMed ID: 19080074
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
WANG J; GAO J; HE J
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
[TBL] [Abstract][Full Text] [Related]
11. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
12. New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.
Nisman B; Nechushtan H; Biran H; Peled N; Gantz-Sorotsky H; Doviner V; Perelman M; Bar J; Onn A; Uziely B; Peretz T
Br J Cancer; 2016 Feb; 114(4):469-76. PubMed ID: 26812573
[TBL] [Abstract][Full Text] [Related]
13. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
[TBL] [Abstract][Full Text] [Related]
14. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer.
Lv ShP; Wang Y; Huang L; Wang F; Zhou JG; Ma H
Asian Pac J Cancer Prev; 2017 Feb; 18(2):391-397. PubMed ID: 28345820
[TBL] [Abstract][Full Text] [Related]
18. [Meta-analysis of diagnostic capability of frequency-doubling technology (FDT) for primary glaucoma].
Liu T; He XG
Zhonghua Yan Ke Za Zhi; 2006 May; 42(5):403-8. PubMed ID: 16762233
[TBL] [Abstract][Full Text] [Related]
19. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
Miyake Y; Kodama T; Yamaguchi K
Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
[TBL] [Abstract][Full Text] [Related]
20. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]